Themis Medicare Limited

BSE:530199 Stock Report

Market Cap: ₹26.4b

Themis Medicare Valuation

Is 530199 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 530199 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 530199 (₹287.05) is trading above our estimate of fair value (₹155.43)

Significantly Below Fair Value: 530199 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 530199?

Key metric: As 530199 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 530199. This is calculated by dividing 530199's market cap by their current earnings.
What is 530199's PE Ratio?
PE Ratio49.9x
Earnings₹529.90m
Market Cap₹26.41b

Price to Earnings Ratio vs Peers

How does 530199's PE Ratio compare to its peers?

The above table shows the PE ratio for 530199 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average48.4x
INDOCO Indoco Remedies
92.4x72.2%₹29.7b
590006 Amrutanjan Health Care
44.9xn/a₹21.4b
507747 TTK Healthcare
26.4xn/a₹21.3b
500672 Novartis India
29.8xn/a₹26.1b
530199 Themis Medicare
49.9xn/a₹26.4b

Price-To-Earnings vs Peers: 530199 is expensive based on its Price-To-Earnings Ratio (49.9x) compared to the peer average (48.4x).


Price to Earnings Ratio vs Industry

How does 530199's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$69.13m
524652 Ind-Swift
2.2xn/aUS$14.23m
No more companies available in this PE range
530199 49.9xIndustry Avg. 36.0xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 530199 is expensive based on its Price-To-Earnings Ratio (49.9x) compared to the Indian Pharmaceuticals industry average (36x).


Price to Earnings Ratio vs Fair Ratio

What is 530199's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

530199 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 530199's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies